skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
abstract
TAKE-HOME MESSAGE
-
In this study, genomic data from 512 patients treated for ovarian
cancer were evaluated to identify mutations associated with chemotherapy
response. ADAMTS mutations, which occurred in 10.4% of patients, were associated with higher response to chemotherapy. After adjusting for BRCA1 and BRCA2 mutations, surgical stage, residual tumor, and patient age, ADAMTS mutations were significantly associated with better overall survival and platinum-free duration. ADAMTS-mutated tumors had higher genome-wide mutation rates compared with ADAMTS wild-type tumors.
- In women with ovarian cancer without BRCA1 or BRCA2 mutations, ADAMTS mutations may contribute to response to chemotherapy.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.